Drug Trial Radar · NCT00660335
Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
Last checked: Nov 19, 2026Latest source record: Dec 3, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
258
Actual
Start
Mar 2008
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Repligen CorporationIndustry
- Sponsor type
- Industry
- First posted
- Apr 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and effectiveness of RG1068 (synthetic human secretin) with MRCP in subjects with abnormalities of the pancreas.
Conditions
- Pancreatitis
Interventions
RG1068 (synthetic human secretin)Drug
Single-dose, IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome measure will be assessed by comparing baseline MRCP images and RG1068-enhanced MRCP images for the presence or absence of pancreatic abnormalities.Time frame: 0 - 10 minutes post dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.